미국의 잠복결핵 감염 감지 시장 규모, 점유율, 동향 분석 보고서 : 검사별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

U.S. Latent Tuberculosis Infection Detection Market Summary

The U.S. latent tuberculosis infection detection market size was estimated at USD 427.61 million in 2025 and is projected to reach USD 651.11 million by 2033, growing at a CAGR of 5.17% from 2026 to 2033. This growth is driven by an increasing risk of developing active tuberculosis infection from latent tuberculosis infection (LTBI), growing funding programs to promote TB diagnosis, aided by technological advancements in diagnostic methods.

According to estimates from the Centers for Disease Control and Prevention (CDC), up to 13 million people in the U.S. are believed to have LTBI, and without preventive treatment, about 5 %-10 % of those infected will develop active TB at some point in their lives.

Moreover, the growing focus on tuberculosis (TB) elimination and preventive care is creating a strong growth opportunity for the LTBI detection market. Public health authorities increasingly recognize that most active TB cases in the U.S. result from reactivation of latent infection rather than recent transmission. As a result, national TB elimination strategies have shifted toward identifying and treating LTBI before it progresses to active disease, placing greater emphasis on early and accurate diagnostic testing.

The risk of incident TB is influenced by various factors, such as age, underlying health conditions, and exposure settings, with older individuals and those in certain environments facing higher risks. Hence, managing LTBI through testing and treatment is crucial in reducing the risk of developing active TB and preventing the spread of the disease. Factors contributing to increased susceptibility to active TB from LTBI include:

U.S. Latent Tuberculosis Infection Detection Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. latent tuberculosis infection detection market report based on test, application, and end use:

• Test Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Interferon Gamma Released Assay (IGRA)
  • QFT
  • T.SPOT
  • Tuberculin Skin Test (TST)
• Application Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Household Contacts With Pulmonary TB
  • PLHIV
  • Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Diagnostic Laboratories
  • Hospitals/Clinics
  • Academic & Research Institutions

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Test
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Objectives
  • 1.3.1. Objective-1
  • 1.3.2. Objective-2
  • 1.3.3. Objective-3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased database
  • 1.5.2. GVR's internal database
  • 1.5.3. Secondary sources
  • 1.5.4. Primary research
• 1.6. Information or Data Analysis
  • 1.6.1. Data analysis models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity flow analysis
    • 1.8.1.1. Approach 1: Commodity flow approach
    • 1.8.1.2. Approach 2: Country-wise market estimation using bottom-up approach
• 1.9. List of Secondary Sources
• 1.10. List of Primary Sources
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Test Snapshot
• 2.3. Application and End-use Snapshot
• 2.4. Competitive Insights

Chapter 3. U.S. Latent Tuberculosis Infection Detection Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook (Latent Tuberculosis Infection Detection Market)
  • 3.1.2. Related/ancillary market outlook (Tuberculosis Diagnostics Market)
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in risk of developing active Tuberculosis Infection from LTBI
    • 3.2.1.2. Increasing Funding Programs to Promote TB Diagnostics
    • 3.2.1.3. Technological Advancements in Diagnostics Methods
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited Awareness and Underdiagnosis of Latent TB
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Growing Focus on TB Elimination and Preventive Care
    • 3.2.3.2. Expansion of Community-Based and Targeted Screening Programs
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Low Disease Visibility and Competing Public Health Priorities
• 3.3. U.S. Latent Tuberculosis Infection Detection Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
• 3.4. Regulatory Framework
• 3.5. Reimbursement Scenario
• 3.6. Payment/ Reimbursement for Immigration Testing
• 3.7. CLIA Labs in the U.S.
  • 3.7.1. List of all the CLIA Labs in the U.S
  • 3.7.2. List of CLIA and NYS Certified Labs that Perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their Volumes
  • 3.7.3. List of Physicians and Volumes Ordered of the Tests Split out by NPI, Geography, and Practice

Chapter 4. U.S. Latent Tuberculosis Infection Detection Market: Test Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Latent Tuberculosis Infection Detection Market: Test Movement Analysis
• 4.3. U.S. Latent Tuberculosis Infection Detection Market by Test Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 4.5. Interferon Gamma Released Assay (IGRA)
  • 4.5.1. Interferon Gamma Released Assay (IGRA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Interferon Gamma Released Assay (IGRA) Market Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 4.5.3. QFT
    • 4.5.3.1. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.2. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 4.5.4. T. SPOT
    • 4.5.4.1. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4.2. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 4.6. Tuberculin Skin Test (TST)
  • 4.6.1. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 5. U.S. Latent Tuberculosis Infection Detection Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Latent Tuberculosis Infection Detection Market: Application Movement Analysis
• 5.3. U.S. Latent Tuberculosis Infection Detection Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 5.5. Household Contacts With Pulmonary TB
  • 5.5.1. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 5.6. PLHIV
  • 5.6.1. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.2. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 6. U.S. Latent Tuberculosis Infection Detection Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Latent Tuberculosis Infection Detection Market: End Use Movement Analysis
• 6.3. U.S. Latent Tuberculosis Infection Detection Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 6.5. Diagnostic Laboratories
  • 6.5.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 6.6. Hospitals/Clinics
  • 6.6.1. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 6.7. Academic & Research Institutions
  • 6.7.1. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2025
• 7.4. Key Company Profiles
  • 7.4.1. QIAGEN
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Euroimmun US
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. bioMerieux
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Oxford Immunotec
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. SD Biosensor, INC.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Quest Diagnostics
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. LabCorp
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. ARUP Laboratories
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Mayo Clinic Laboratories
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. BioReference Laboratories
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Par Pharmaceutical, Inc.
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives